The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Herpes Zoster Vaccination

  • Kim, Kyung Hoon (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University)
  • Received : 2013.06.17
  • Accepted : 2013.06.20
  • Published : 2013.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Varicella (chickenpox) is a highly contagious airborne disease caused by primary infection with the varicella zoster virus (VZV). Following the resolution of chickenpox, the virus can remain dormant in the dorsal sensory and cranial ganglion for decades. Shingles (herpes zoster [HZ]) is a neurocutaneous disease caused by reactivation of latent VZV and may progress to postherpetic neuralgia (PHN), which is characterized by dermatomal pain persisting for more than 120 days after the onset of HZ rash, or "well-established PHN", which persist for more than 180 days. Vaccination with an attenuated form of VZV activates specific T-cell production, thereby avoiding viral reactivation and development of HZ. It has been demonstrated to reduce the occurrence by approximately 50-70%, the duration of pain of HZ, and the frequency of subsequent PHN in individuals aged ${\geq}50$ years in clinical studies. However, it has not proved efficacious in preventing repeat episodes of HZ and reducing the severity of PHN, nor has its long-term efficacy been demonstrated. The most frequent adverse reactions reported for HZ vaccination were injection site pain and/or swelling and headache. In addition, it should not be administrated to children, pregnant women, and immunocompromised persons or those allergic to neomycin or any component of the vaccine.

Keywords

References

  1. De Clercq E. Antivirals: past, present and future. Biochem Pharmacol 2013; 85: 727-44. https://doi.org/10.1016/j.bcp.2012.12.011
  2. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48 Suppl 1: S2-7. https://doi.org/10.1016/S1386-6532(10)70002-0
  3. Kinchington PR, Leger AJ, Guedon JM, Hendricks RL. Herpes simplex virus and varicella zoster virus, the house guests who never leave. Herpesviridae 2012; 3: 5. https://doi.org/10.1186/2042-4280-3-5
  4. Quinlivan M, Breuer J. Molecular studies of varicella zoster virus. Rev Med Virol 2006; 16: 225-50. https://doi.org/10.1002/rmv.502
  5. Temin HM, Baltimore D. RNA-directed DNA synthesis and RNA tumor viruses. Adv Virus Res 1972; 17: 129-86. https://doi.org/10.1016/S0065-3527(08)60749-6
  6. Quinlivan M, Breuer J. Molecular and therapeutic aspects of varicella-zoster virus infection. Expert Rev Mol Med 2005; 7: 1-24.
  7. Weigle KA, Grose C. Molecular dissection of the humoral immune response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and reactivation. J Infect Dis 1984; 149: 741-9. https://doi.org/10.1093/infdis/149.5.741
  8. Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis 1983; 148: 200-5. https://doi.org/10.1093/infdis/148.2.200
  9. Gershon AA, Steinberg SP, Gelb L. Clinical reinfection with varicella-zoster virus. J Infect Dis 1984; 149: 137-42. https://doi.org/10.1093/infdis/149.2.137
  10. Johnson JA, Bloch KC, Dang BN. Varicella reinfection in a seropositive physician following occupational exposure to localized zoster. Clin Infect Dis 2011; 52: 907-9. https://doi.org/10.1093/cid/cir033
  11. Thakur R, Kent JL, Dworkin RH. Herpes zoster and postherpetic neuralgia. In: Bonica's management of pain. 4th ed. Edited by Fishman S, Ballantyne J, Rathmell JP, Bonica JJ. Philadelphia (PA), Lippincott Williams & Wilkins. 2010, pp 338-57.
  12. Flatt A, Breuer J. Varicella vaccines. Br Med Bull 2012; 103: 115-27. https://doi.org/10.1093/bmb/lds019
  13. Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis 2008; 197 Suppl 2: S224-7. https://doi.org/10.1086/522162
  14. Goldman GS, King PG. Review of the United States universal varicella vaccination program: herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine 2013; 31: 1680-94. https://doi.org/10.1016/j.vaccine.2012.05.050
  15. Hambleton S, Steinberg SP, Larussa PS, Shapiro ED, Gershon AA. Risk of herpes zoster in adults immunized with varicella vaccine. J Infect Dis 2008; 197 Suppl 2: S196-9. https://doi.org/10.1086/522131
  16. Goldman GS. Universal varicella vaccination: efficacy trends and effect on herpes zoster. Int J Toxicol 2005; 24: 205-13. https://doi.org/10.1080/10915810591000659
  17. Goldman GS. Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology. Vaccine 2005; 23: 3349-55. https://doi.org/10.1016/j.vaccine.2003.10.042
  18. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84. https://doi.org/10.1056/NEJMoa051016
  19. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54: 922-8. https://doi.org/10.1093/cid/cir970
  20. Shapiro M, Kvern B, Watson P, Guenther L, McElhaney J, McGeer A. Update on herpes zoster vaccination: a family practitioner's guide. Can Fam Physician 2011; 57: 1127-31.
  21. Nahm FS, Kim SH, Kim HS, Shin JW, Yoo SH, Yoon MH, et al. Survey on the treatment of postherpetic neuralgia in Korea; multicenter study of 1,414 patients. Korean J Pain 2013; 26: 21-6. https://doi.org/10.3344/kjp.2013.26.1.21
  22. Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev 2012; 10: CD008858.

Cited by

  1. Medications in Treatment of Postherpetic Neuralgia vol.27, pp.1, 2014, https://doi.org/10.3344/kjp.2014.27.1.1
  2. Risk Factor and Prevention of Postherpetic Neuralgia vol.28, pp.3, 2015, https://doi.org/10.3344/kjp.2015.28.3.167
  3. Earlier treatment improves the chances of complete relief from postherpetic neuralgia vol.30, pp.3, 2017, https://doi.org/10.3344/kjp.2017.30.3.214
  4. The positive duration of varicella zoster immunoglobulin M antibody test in herpes zoster vol.95, pp.33, 2016, https://doi.org/10.1097/MD.0000000000004616
  5. Herpes zoster ophthalmicus associated with abducens palsy vol.5, pp.2, 2013, https://doi.org/10.4103/0976-3147.131673
  6. Chickenpox: An update vol.49, pp.1, 2013, https://doi.org/10.1016/j.medmal.2018.04.395
  7. Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia vol.33, pp.3, 2013, https://doi.org/10.3344/kjp.2020.33.3.201
  8. Using the Past to Maximize the Success Probability of Future Anti-Viral Vaccines vol.8, pp.4, 2020, https://doi.org/10.3390/vaccines8040566